Brazil's health regulator Anvisa said on Monday it has suspended clinical trials of China's Sinovac COVID-19 vaccine, following a "severe incident".
The health regulator in a statement referred to the "incident", that occurred on October 29, without revealing further information.
"National Health Surveillance Agency ANVISA has temporarily suspended human testing of the Chinese vaccine Coronavac due to 'a serious adverse effect,'" Sputnik reported, citing Anvisa's statement.
President Jair Bolsonaro on Monday had said that their government would buy whatever coronavirus vaccine is certified by Anvisa.
Brazil's move to suspend the clinical trials of the Chinese vaccine comes amid a rising number of coronavirus cases. On Monday, the country registered 10,917 new cases, taking the country's tally to 5,590,025, while deaths rose to 161,106.
The setback for China's CoronaVac vaccine came in the backdrop of US pharmaceutical giant Pfizer's announcement that said its own vaccine candidate had shown 90 per cent effectiveness.
"I would say it is a historical moment. Something like this has never happened before. First of all, the world was faced with such a terrible situation, the pandemic, and being able in such a short time to go through what usually takes many years," Washington Post quoted Kathrin Jansen, head of vaccine research and development at Pfizer, as saying.
Both the Sinovac and Pfizer vaccines are in the final stage of testing before regulatory approval.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU